Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 18, 2024 07:00 ET
|
Entrada Therapeutics, Inc.
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Entrada Therapeutics Reports Third Quarter 2024 Financial Results
November 05, 2024 07:00 ET
|
Entrada Therapeutics, Inc.
Entrada Therapeutics Reports Third Quarter 2024 Financial Results
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
October 09, 2024 07:00 ET
|
Entrada Therapeutics, Inc.
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development
September 24, 2024 07:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing...
Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program
September 06, 2024 07:00 ET
|
Entrada Therapeutics, Inc.
Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program
Entrada Therapeutics Reports Second Quarter 2024 Financial Results
August 13, 2024 07:00 ET
|
Entrada Therapeutics, Inc.
Entrada Therapeutics Reports Second Quarter 2024 Financial Results
Entrada Therapeutics Announces $100 Million Registered Direct Offering
June 24, 2024 07:15 ET
|
Entrada Therapeutics, Inc.
BOSTON, June 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new...
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
June 24, 2024 06:00 ET
|
Entrada Therapeutics, Inc.
– ENTR-601-44 was well-tolerated in healthy volunteers with no serious adverse events, no drug-related adverse events and no clinically significant changes or trends noted in vital signs,...
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
June 03, 2024 07:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new...
Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
May 16, 2024 07:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, May 16, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class...